K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

By C. Karapetis, S. Khambata-Ford, D. Jonker, C. O'Callaghan, D. Tu, N. Tebbutt, R. Simes, H. Chalchal, J. Shapiro, S. Robitaille and 6 more. New England Journal of Medicine, 2008

3,669 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/e2b4a1b50c8739fb894ba176c2d82c49f21f45f0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Jérôme Galon
2. Fortunato Ciardiello
3. P. Jänne

In Pulmonary and Respiratory Medicine

1. Kenichi Sugihara
2. P. Jänne

Citations in the corpus

• Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012, background): “• The usefulness of anti-EGFR antibody drugs has been reported in metastatic colorectal cancer without KRAS gene mutations [38–41, 47, 53, 55, 85–90].”
• Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours (2013, background): “Somatic mutations in codons 12, 13 and 61 of KRAS , and more recently NRAS , predict innate resistance to mAbs targeting epidermal growth factor receptor [18–20].”
• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, background): “Retrospective analyses of pivotal clinical trials for the epidermal growth factor receptor (EGFR) monoclonal antibodies, cetuximab and panitumumab, have shown that patients with mCRC whose tumours contain activating mutations in KRAS exon 2 (codons 12/13), do not derive a benefit from EGFR monoclona”
• Subgroup identification based on differential effect search—A recursive partitioning method for establishing response to treatment in patient subpopulations (2011, background): “K-Ras status of patients with colorectal cancer treated with the monoclonal antibodies, panitumumab [6] or cetuximab [7], serves as an example of a predictive covariate.”
• ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. (2012, background): “Epithelial growth factor receptor (EGFR) inhibitors • KRAS mutation precludes efficacy of treatment with antiepithelial growth factor receptor (EGFR) antibodies and KRAS status determination is therefore mandatory before treatment [35] [I, A].”
• Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. (2010, methodology): “KRAS mutation analysis was performed by direct sequencing as described previously.(13) All centers participating in the NCIC CTG CO.”